生殖支原体的联合治疗及parC突变检测提升治愈率的新见解
在墨尔本性健康中心开展的前瞻性评估中,基于大环内酯耐药指导的联合抗菌治疗用于生殖支原体感染:大环内酯敏感者接受多西环素+阿奇霉素,耐药者接受多西环素+莫西沙星。敏感者治愈率93.0%,耐药者85.0%;parC S83/D87无突变者治愈率98.3%,S83I突变者失败率62.5%。
要点
- 大环内酯敏感MG用多西环素+阿奇霉素治愈率93.0%,耐药MG用多西环素+莫西沙星治愈率85.0%。
- parC S83/D87无突变者多西环素+莫西沙星治愈率98.3%,S83I突变者失败率62.5%。
- 副作用常见(40%-46%),主要为轻度胃肠道反应。
核心结论
- 多西环素+阿奇霉素对大环内酯敏感MG感染治愈率高;但在parC S83I突变高流行(23%)背景下,多西环素+莫西沙星仅治愈85%。
- S83/D87野生型感染接受多西环素+莫西沙星治愈率高,支持在临床中采用parC耐药/敏感检测策略。
研究设计与样本
- 前瞻性评估2019年8月至2020年12月在墨尔本性健康中心开展,评估耐药指导的联合抗菌治疗对MG的疗效与耐受性。
- 所有患者先接受7天多西环素,再根据大环内酯耐药谱给予联合治疗:敏感者多西环素+阿奇霉素(第1天1 g,第2-4天500 mg),耐药者多西环素+莫西沙星(400 mg每日一次,共7天)。
- 在抗菌治疗完成后推荐14-28天进行治愈检测,记录依从性和不良反应;对parC基因单核苷酸多态性(SNPs)进行测序,分析其与大环内酯耐药感染莫西沙星治疗结局的关联。
主要发现
- 100例大环内酯敏感MG患者接受多西环素+阿奇霉素,93例治愈(93.0%;95% CI,86.1-97.1)。
- 247例大环内酯耐药MG患者接受多西环素+莫西沙星,210例治愈(85.0%;95% CI,80.0-89.2)。
- 164例(66%)大环内酯耐药感染有parC测序结果,29%存在parC S83或D87位点SNPs(23%为S83I)。
- parC S83/D87无SNPs者接受多西环素+莫西沙星后治愈率98.3%(95% CI,93.9-99.8);parC S83I-SNP存在者失败率62.5%(95% CI,45.8-77.3)。
- 副作用常见(40%-46%),主要为轻度胃肠道反应。
临床怎么用
- 作者认为,S83/D87野生型感染接受多西环素+莫西沙星治愈率高,支持在临床中采用parC耐药/敏感检测策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mycoplasma genitalium (MG) infection is challenging to cure because of rising antimicrobial resistance and limited treatment options. METHODS: This was a prospective evaluation of the efficacy and tolerability of resistance-guided combination antimicrobial therapy for MG treatment at Melbourne Sexual Health Centre (August 2019-December 2020). All patients received 7 days of doxycycline before combination therapy based on the macrolide-resistant profile. Macrolide-susceptible infections received combination doxycycline + azithromycin (1 g, day 1; 500 mg, days 2-4) and macrolide-resistant infections combination doxycycline + moxifloxacin (400 mg daily for 7 days). Adherence and adverse effects were recorded at test-of-cure, recommended 14-28 days after antimicrobial completion. Sequencing was performed to determine the prevalence of single nucleotide polymorphisms (SNPs) in the parC gene and their association with moxifloxacin treatment outcomes in macrolide-resistant infections. RESULTS: Of 100 patients with macrolide-susceptible MG treated with doxycycline + azithromycin, 93 were cured (93.0%; 95% confidence interval [CI], 86.1-97.1). Of 247 patients with macrolide-resistant MG receiving doxycycline + moxifloxacin, 210 were cured (85.0%; 95% CI, 80.0-89.2). parC sequencing was available for 164 (66%) macrolide-resistant infections; 29% had SNPs at parC S83 or D87 (23% S83I). The absence of SNPs at parC S83/D87 was associated with 98.3% cure (95% CI, 93.9-99.8) following doxycycline + moxifloxacin. The presence of the parC S83I-SNP was associated with failure in 62.5% (95% CI, 45.8-77.3). Side effects were common (40%-46%) and predominantly mild and gastrointestinal. CONCLUSIONS: Combination doxycycline + azithromycin achieved high cure for macrolide-susceptible infections. However, in the context of a high prevalence of the parC S83I mutation (23%) in macrolide-resistant infections, doxycycline + moxifloxacin cured only 85%. Infections that were wild-type for S83/D87 experienced high cure following doxycycline + moxifloxacin, supporting the use of a parC-resistance/susceptibility testing strategy in clinical care.
引用
- Vodstrcil LA, Plummer EL, Doyle M, et al. Combination Therapy for Mycoplasma genitalium, and New Insights Into the Utility of parC Mutant Detection to Improve Cure. Clin Infect Dis. 2022. PMID: 34984438. doi:10.1093/cid/ciab1058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。